Residual antimalarials in malaria patients from Tanzania--implications on drug efficacy assessment and spread of parasite resistance.
BACKGROUND
Repeated antimalarial treatment for febrile episodes and self-treatment are common in malaria-endemic areas. The intake of antimalarials prior to participating in an in vivo study may alter treatment outcome and affect the interpretation of both efficacy and safety outcomes. We report the findings from baseline plasma sampling of malaria patients prior to inclusion into an in vivo study in Tanzania and discuss the implications of residual concentrations of antimalarials in this setting.


RESULTS
In an in vivo study conducted in a rural area of Tanzania in 2008, baseline plasma samples from patients reporting no antimalarial intake within the last 28 days were screened for the presence of 14 antimalarials (parent drugs or metabolites) using liquid chromatography-tandem mass spectrometry. Among the 148 patients enrolled, 110 (74.3%) had at least one antimalarial in their plasma: 80 (54.1%) had lumefantrine above the lower limit of calibration (LLC = 4 ng/mL), 7 (4.7%) desbutyl-lumefantrine (4 ng/mL), 77 (52.0%) sulfadoxine (0.5 ng/mL), 15 (10.1%) pyrimethamine (0.5 ng/mL), 16 (10.8%) quinine (2.5 ng/mL) and none chloroquine (2.5 ng/mL).


CONCLUSIONS
The proportion of patients with detectable antimalarial drug levels prior to enrollment into the study is worrying. Indeed artemether-lumefantrine was supposed to be available only at government health facilities. Although sulfadoxine-pyrimethamine is only recommended for intermittent preventive treatment in pregnancy (IPTp), it was still widely used in public and private health facilities and sold in drug shops. Self-reporting of previous drug intake is unreliable and thus screening for the presence of antimalarial drug levels should be considered in future in vivo studies to allow for accurate assessment of treatment outcome. Furthermore, persisting sub-therapeutic drug levels of antimalarials in a population could promote the spread of drug resistance. The knowledge on drug pressure in a given population is important to monitor standard treatment policy implementation.
Hodel
Eva Maria
EM
Swiss Tropical Institute, Basel, Switzerland.
Kabanywanyi
Abdunoor Mulokozi
AM
Malila
Aggrey
A
Zanolari
Boris
B
Mercier
Thomas
T
Beck
Hans-Peter
HP
Buclin
Thierry
T
Olliaro
Piero
P
Decosterd
Laurent Arthur
LA
Genton
Blaise
B
D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D000962:Antimalarials / Q000097:blood* / Q000494:pharmacology* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004350:Drug Residues / Q000032:analysis*; D004351:Drug Resistance / Q000187:drug effects; D005260:Female; D005843:Geography; D006801:Humans; D007223:Infant; D008288:Malaria / Q000097:blood* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010271:Parasites / Q000187:drug effects*; D013413:Sulfadoxine / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D013636:Tanzania; D016896:Treatment Outcome; D055815:Young Adult
D000962:Antimalarials; D013413:Sulfadoxine